21 Results for "

cRGD

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "cRGD" in MCE Product Catalog:

Cat. No.: HY-172464
DSPE-PEG2000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG2000-cRGD can be used for drug delivery .
loading...
    loading...
Cat. No.: HY-P6438
CAS No.: 2665674-77-9
Target:  

Integrin

Research Areas:  

Others Cancer

Alkyne-cRGD is an integrin ligand. Alkyne-cRGD can be used in the study of degraders. Alkyne-cRGD undergoes copper-catalyzed azide-alkyne cycloaddition reaction .
loading...
    loading...
Cat. No.: HY-D2440
cRGD-PEG-Cy3 is a Cy3 (HY-D0822) labeled cRGD-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. cRGD can be used to modify lipid for improved stability .
loading...
    loading...
Cat. No.: HY-178819
Research Areas:  

Cancer

NM-001 is a theranostic prodrug that targets ανβ3 integrin. NM-001 consists of cRGD and GFLG peptides, a DCM fluorophore and Chlorambucil (HY-13593). NM-001 internalizes into lysosomes of tumor cells via the cRGD peptide, and generates NM-002 (HY-178820) and Chlorambucil through intracellular cleavage at the GFLG peptide by overexpressed Cathepsin B (CTSB). NM-001 exhibits green fluorescence under physiological conditions, and converts to NIR fluorescence by CTSB activation. NM-001 has significant antitumor activity with low toxicity in HeLa cell xenografts mouse models. NM-001 can be used for real-time drug release monitoring research .
loading...
    loading...
Cat. No.: HY-172465
DSPE-PEG5000-cRGD is a PEG conjugate composed of DSPE and the αvβ3-targeting peptide (cRGD). The cRGD peptide specifically binds to αvβ3 on the surface of various cancer cells and neovascular cells. DSPE-PEG5000-cRGD is applicable for research on drug delivery, cancer and vascular diseases .
loading...
    loading...
Cat. No.: HY-P3448S
Synonyms: CEND-1-13C6,15N2; iRGD-13C6,15N2; LSTA1-13C6,15N2
Certepetide- 13C6, 15N2 (CEND-1- 13C6, 15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
loading...
    loading...
Cat. No.: HY-172463
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .
loading...
    loading...
Cat. No.: HY-172464A
DSPE-PEG3400-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG3400-cRGD can be used for drug delivery .
loading...
    loading...
Cat. No.: HY-P10783
Research Areas:  

Cancer

BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .
loading...
    loading...
Cat. No.: HY-187311A
Alkyne-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: alkyne (propargyl/alkyne linker) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. Alkyne-PEG2000-cRGD does not contain a lipid anchoring group but instead provides a terminal reactive site for post-assembly ligand or probe conjugation on PEGylated nanoparticles.
loading...
    loading...
Cat. No.: HY-184578
DOPE-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184578A
DOPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184578B
DOPE-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184578C
DOPE-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184579
DMG-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184579A
DMG-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184579B
DMG-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-184579C
DMG-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-187237A
DPPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dipalmitoylphosphatidylethanolamine (DPPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DPPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...
Cat. No.: HY-187244A
DSG-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: distearoylglycerol (DSG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DSG-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
loading...
    loading...